Compare ENHA & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENHA | HQL |
|---|---|---|
| Founded | N/A | 1992 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Investment Managers |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.1M | 689.4M |
| IPO Year | 2025 | N/A |
| Metric | ENHA | HQL |
|---|---|---|
| Price | $1.57 | $19.71 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 137.4K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $25.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.48 | $13.88 |
| 52 Week High | $4.60 | $22.67 |
| Indicator | ENHA | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 30.19 | 36.86 |
| Support Level | $1.50 | $16.21 |
| Resistance Level | $1.71 | $21.32 |
| Average True Range (ATR) | 0.13 | 0.46 |
| MACD | 0.04 | -0.24 |
| Stochastic Oscillator | 27.26 | 3.89 |
Enhanced Group Inc develops and sells sports and performance-related products intended for use by athletes and consumers. Its offerings focus on products associated with physical performance, health, and recovery. Its two principal offerings include: (i) the Enhanced Games, a live, multi-sport competition platform designed to showcase both "Enhanced" and "Non-Enhanced" athletes pursuing world-record performances under medically supervised conditions; and (ii) Live Enhanced, a direct-to-consumer digital and clinician-guided wellness platform offering evidence-based protocols, supplements, and coaching for consumers seeking to improve health, longevity, and well-being. The majority of the company's revenue is derived from products associated with physical performance, health, and recovery.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.